Microvessel density ≥60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: Results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 4, 2007, Pages 406-419

  Calvin, Douglas P ^a   Hammond, M E ^b   Pajak, Thomas F ^c   Trotti, Andy M ^d   Meredith, Ruby F ^e   Rotman, Marvin ^f   Jones, Christopher U ^g   Byhardt, Roger W ^h   Demas, W F ⁱ   Ang, K Kian ^j   Fu, Karen K ^k  

^a Lakeland Regional Cancer Center   (United States)

^b LDS HOSPITAL   (United States)

^c Statistical Consultant   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g Radiological Associates of Sacramento Medical Group Inc   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ AKRON CITY HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIDASE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHODOLOGY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; VASCULARIZATION; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; HEAD AND NECK TUMOR; METABOLISM; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL RATE; VON WILLEBRAND FACTOR;

EID: 34548391012     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3180342fd4     Document Type: Article

References (60)

1. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977;15:53-58.
2. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, et al, eds. The Molecular Basis of Cancer. Philadelphia: Saunders, 1995:206-232.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1995;1:27-31.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
5. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
6. Hall MC, Troncoso P, Pollack A, et al. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology. 1994;44:869-875.
7. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
8. Igarashi M, Dhar DK, Kubota H, et al. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer. 1998;82:1225-1232.
9. Shih C-H, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000;6:1161-1168.
10. Brawer MK. Quantitative microvessel density: a staging and prognostic marker for human prostatic carcinoma. Cancer. 1996;78:345-349.
11. Silberman MA, Partin AW, Veltri RW, et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 1997;79:772-779.
12. Artese L, Rubini C, Ferrero G, et al. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res. 2001;21:689-696.
13. Alcalde RE, Terakado N, Otsuki K, et al. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology. 1997;54:324-328.
14. Roychowdhury DF, Tseng A, Fu KK, et al. New prognostic factors in nasopharyngeal carcinoma [Abstract]. Proc Am Soc Clin Oncol. 1995;20-23.
15. Roychowdhury DF, Tseng A, Fu KK, et al. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and C-erbB2 expression. Cancer. 1996;77:1419-1426.
16. Albo D, Granick MS, Jhala N, et al. The relationship of angiogenesis to biological activity in human squamous cell carcinoma of the head and neck. Ann Plast Surg. 1994;32:588-594.
17. Kupisz K, Chibowski D, Klatka J, et al. Tumor angiogenesis in patients with laryngeal cancer. Eur Arch Otorhinolaryngol. 1999;256:303-305.
18. Carrau RL, Barnes EL, Snyderman CH, et al. Tumor angiogenesis as a predictor of tumor aggressiveness and metastatic potential in squamous cell carcinoma of the head and neck. Invasion Metastasis. 1995;15:197-202.
19. Gleich LL, Biddinger PW, Duperier FD, et al. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: a clinical-pathologic correlation. Head Neck. 1997;19:276-280.
20. Zatterstrom UK, Brun E, Willen R, et al. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck. 1995;17:312-318.
21. Dray TG, Hardin NJ, Sofferman RA. Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol. 1995;104:724-729.
22. Delides GS, Venizelos J, Revesz L, et al. Vascularization and curability of Stage III and IV nasopharyngeal tumors. J Cancer Res Clin Oncol. 1988;114:321-323.
23. Moriyama M, Kamagai S, Kawashirir S, et al. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol. 1997;33:369-374.
24. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs. 1997;15:39-48.
25. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature. 1998;394:287-291.
26. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378.
27. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998;58:5686-5689.
28. Gupta VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 2002;8:47-54.
29. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155-1159.
30. Myoung H, Seong-Doo H, Young-Youn K, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett. 2001;163:191-200.
31. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994;54:2582-2590.
32. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to a reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61:2413-2419.
33. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365-375.
34. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
36. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep. 1966;50:163-170.
37. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley, 1980.
38. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
39. Cox DR. Regression models and life-tables. J R Statist Soc Ser B. 1972;34:187-220.
40. Pajak TF, Clark GM, Sargent DJ, et al. Statistical issues in tumor marker studies. Arch Pathol Lab Med. 2000;124:1011-1015.
41. Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys. 2000;48:17-25.
42. Brun E, Zatterstrom U, Kjellen E, et al. Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol. 2001;40:491-496.
43. Koukourakis M, Giatromanolaki A, Sivridis E, et al. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res. 2001;21:4301-4310.
44. Deleted in proof.
45. Foote RL, Weidner N, Harris J, et al. Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys. 2005;61:745-753.
46. Zatterstrom UK, Brun E, Willen R, et al. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck. 1995;17:312-318.
47. Yoshinori I, Tomoyuki K, Tomoyuki Y, et al. Microvessel density predicts the radiosensitivity of metastatic head and neck squamous cell carcinoma in cervical lymph nodes. Int J Oncol. 2001;19:1127-1132.
48. Kamijo T, Yokose T, Hasebe T, et al. Potential role of microvessel density in predicting radiosensitivity of T1 and T2 stage laryngeal squamous cell carcinoma treated with radiotherapy. Clin Cancer Res. 2000;6:3159-3165.
49. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996;88:583-589.
50. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
51. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804.
52. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
53. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949-955.
54. Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer. 1993;55:739-744.
55. Gasparini G, Bevilacqua P, Bonoldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res. 1995;1:1375-1383.
56. Sauter ER, Nesbit M, Watson JC, et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999;5:775-782.
57. Franchi A, Gallo O, Paglierani M, et al. Inducible nitric oxide synthase expression in laryngeal neoplasia: correlation with angiogenesis. Head Neck. 2002;24:16-23.
58. Riedel F, Gotte K, Schwalb J, et al. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol. 2000;17:1099-1105.
59. Yao L, Shao Y-L, Itoh S, et al. Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival. Oral Oncol. 2000;36:539-544.
60. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001;61:39-44.